Gsk (GLAXF) Cash & Equivalents (2009 - 2026)

Gsk's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $4.6 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 17.47% year-over-year to $4.6 billion; the TTM figure through Mar 2026 stood at $4.6 billion (down 17.47% YoY), while the FY2025 annual figure was $4.5 billion, down 9.46% from the prior year.
• Cash & Equivalents was $4.6 billion for Q1 2026 at Gsk, up from $4.5 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $14.7 billion in Q1 2022 to a low of $3.5 billion in Q1 2023.
• Historically, Cash & Equivalents has averaged $5.1 billion across 5 years, with a median of $4.4 billion in 2022.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents jumped 124.34% in 2022, then sank 76.13% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $4.4 billion in 2022, then declined by 16.55% to $3.6 billion in 2023, then surged by 36.31% to $5.0 billion in 2024, then fell by 9.03% to $4.5 billion in 2025, then rose by 2.7% to $4.6 billion in 2026.
• The last three Cash & Equivalents figures came in at $4.6 billion (Q1 2026), $4.5 billion (Q4 2025), and $4.4 billion (Q3 2025), per Business Quant data.